News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
129,477 Results
Type
Article (4327)
Company Profile (88)
Press Release (125062)
Section
Business (42123)
Career Advice (208)
Deals (6160)
Drug Delivery (13)
Drug Development (17434)
Employer Resources (18)
FDA (1487)
Job Trends (2782)
News (66254)
Policy (3645)
Tag
2024 BioCapital Digital (2)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Digital (7)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (6)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 Biotech Bay Standard (1)
Academia (292)
Adcomms (1)
Allergies (16)
Alliances (11483)
ALS (27)
Alzheimer's disease (322)
Antibody-drug conjugate (ADC) (25)
Approvals (1498)
Artificial intelligence (55)
Autoimmune disease (8)
Automation (3)
Bankruptcy (38)
Best Places to Work (2253)
BIOSECURE Act (13)
Biosimilars (6)
Biotechnology (85)
Bladder cancer (19)
Brain cancer (6)
Breast cancer (62)
Cancer (516)
Cardiovascular disease (16)
Career advice (196)
Career pathing (4)
CAR-T (53)
Cell therapy (161)
Cervical cancer (6)
Clinical research (14078)
Collaboration (239)
Compensation (99)
Complete response letters (2)
COVID-19 (429)
CRISPR (8)
C-suite (96)
Cystic fibrosis (25)
Data (552)
Depression (7)
Diabetes (47)
Diagnostics (696)
Digital health (1)
Diversity, equity & inclusion (8)
Drug discovery (42)
Drug pricing (5)
Drug shortages (2)
Duchenne muscular dystrophy (20)
Earnings (12485)
Editorial (4)
Employer resources (18)
Events (24586)
Executive appointments (244)
FDA (1702)
Featured Employer (13)
Frontotemporal dementia (5)
Funding (208)
Gene editing (21)
Generative AI (6)
Gene therapy (79)
GLP-1 (107)
Government (340)
Guidances (8)
Healthcare (1537)
Huntington's disease (6)
IgA nephropathy (6)
Immunology and inflammation (24)
Indications (9)
Infectious disease (455)
Inflammatory bowel disease (51)
Inflation Reduction Act (1)
Influenza (16)
Intellectual property (33)
Interviews (17)
IPO (2928)
IRA (4)
Job creations (665)
Job search strategy (184)
Kidney cancer (1)
Labor market (7)
Layoffs (38)
Legal (638)
Liver cancer (12)
Lung cancer (39)
Lymphoma (47)
Machine learning (1)
Management (4)
Manufacturing (75)
MASH (9)
Medical device (401)
Medtech (401)
Mergers & acquisitions (3411)
Metabolic disorders (109)
Multiple sclerosis (23)
NASH (1)
Neurodegenerative disease (16)
Neuropsychiatric disorders (3)
Neuroscience (440)
NextGen: Class of 2025 (858)
Non-profit (273)
Northern California (769)
Now hiring (4)
Obesity (56)
Opinion (38)
Ovarian cancer (29)
Pain (19)
Pancreatic cancer (19)
Parkinson's disease (34)
Partnered (4)
Patents (51)
Patient recruitment (26)
Peanut (12)
People (16395)
Pharmaceutical (8)
Phase I (5584)
Phase II (6723)
Phase III (3451)
Pipeline (295)
Podcasts (2)
Policy (23)
Postmarket research (209)
Preclinical (2396)
Press Release (51)
Prostate cancer (18)
Psychedelics (2)
Radiopharmaceuticals (46)
Rare diseases (64)
Real estate (1442)
Recruiting (10)
Regulatory (2947)
Reports (13)
Research institute (297)
Resumes & cover letters (20)
RSV (4)
Schizophrenia (12)
Series A (38)
Series B (28)
Service/supplier (2)
Sickle cell disease (11)
Southern California (708)
Special edition (2)
Spinal muscular atrophy (36)
Sponsored (4)
Startups (990)
State (1)
Stomach cancer (2)
Supply chain (13)
The Weekly (2)
United States (5842)
Vaccines (74)
Venture capitalists (7)
Webinars (6)
Weight loss (20)
Women's health (4)
Worklife (2)
Date
Today (31)
Last 7 days (180)
Last 30 days (748)
Last 365 days (8930)
2025 (2192)
2024 (9162)
2023 (9916)
2022 (12030)
2021 (12665)
2020 (9876)
2019 (6687)
2018 (5295)
2017 (6083)
2016 (5596)
2015 (6439)
2014 (4927)
2013 (4062)
2012 (4402)
2011 (4871)
2010 (4514)
Location
Africa (137)
Alabama (27)
Alaska (1)
Arizona (25)
Arkansas (2)
Asia (8483)
Australia (1991)
California (1771)
Canada (512)
China (103)
Colorado (29)
Connecticut (63)
Delaware (22)
Europe (18465)
Florida (163)
Georgia (25)
Idaho (10)
Illinois (121)
India (4)
Indiana (91)
Iowa (1)
Japan (32)
Kansas (11)
Kentucky (2)
Louisiana (1)
Maine (2)
Maryland (207)
Massachusetts (1294)
Michigan (65)
Minnesota (91)
Missouri (7)
Montana (8)
Nebraska (2)
Nevada (4)
New Hampshire (5)
New Jersey (392)
New Mexico (6)
New York (430)
North Carolina (257)
North Dakota (3)
Northern California (769)
Ohio (37)
Oklahoma (5)
Oregon (4)
Pennsylvania (355)
Puerto Rico (3)
Rhode Island (4)
South America (198)
South Carolina (1)
Southern California (708)
Tennessee (15)
Texas (205)
Utah (18)
Virginia (10)
Washington D.C. (7)
Washington State (304)
Wisconsin (5)
129,477 Results for "insilico biotechnology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clinical research
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and was well-tolerated across all dosing groups.
November 12, 2024
·
2 min read
·
Heather McKenzie
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
·
4 min read
·
Heather McKenzie
Press Releases
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
February 20, 2025
·
5 min read
Press Releases
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation
December 12, 2024
·
6 min read
Press Releases
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
February 25, 2025
·
15 min read
Press Releases
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
January 10, 2025
·
5 min read
Press Releases
Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease
January 8, 2025
·
7 min read
GNQ Insilico’s AI-Driven Digital Twin Platform Shows Promising Results in First Virtually Simulated Clinical Drug Trial
Trenchant Technologies Capital (CSE: AITT) (OTC: AITTF) (FSE: 5730) “Trenchant” or “the Company”), is pleased to announce that its portfolio company GNQ Insilico (“GNQ”) has demonstrated promising results in synthesizing digital twins of human patients, and simulating the effects of an infertility drug on these digital replicas using its proprietary AI-driven platform.
June 18, 2024
·
6 min read
In-silico Drug Discovery Market to Reach USD 40.3 Billion to 2031 with a CAGR of 18.05% from 2024
“In-silico Drug Discovery Market” in terms of revenue was estimated to be worth $10.9 Bn in 2023 and is poised to reach $40.3 Bn by 2031, growing at a CAGR of 18.05% from 2024 to 2031 according to a new report by InsightAce Analytic.
April 30, 2024
·
6 min read
Insilico CEO Alex Zhavoronkov Discusses AI Drug Discovery
The CEO of Insilico Medicine, which recently became the first company to launch Phase II trials for a drug developed using generative AI, spoke with BioSpace about the rise of the technology.
January 17, 2024
·
3 min read
·
Tyler Patchen
1 of 12,948
Next